Bio-Rad Labs (BIO) Tops Q4 EPS by 4c; offers outlook

Go back to Bio-Rad Labs (BIO) Tops Q4 EPS by 4c; offers outlook

Bio-Rad Labs (BIO) PT Lowered to $400 at Citi

February 14, 2025 9:19 AM EST

Citi analyst Patrick Donnelly lowered the price target on Bio-Rad Labs (NYSE: BIO) to $400.00 (from $450.00) while maintaining a Buy rating.

The analyst comments "BIO guided core FY25 to grow +1.5-3.5% vs. consensus of +2.5%, with Life Sci at +1.5-3.5% vs. Dx at +2-3%. GM /... More